References
- Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3:497–516.
- Briley LD, Phillips CM. Cutaneous mastocytosis: a review focusing on the pediatric population. Clin Pediatr (Phila). 2008;47:757–761.
- Vano-Galvan S, De la Hoz B, Nuñez R, Jaen P. Indolent systemic mastocytosis. Isr Med Assoc J. 2010;12:185–187.
- Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603–625.
- Boissan M, Feger F, Guillosson JJ, Arock M. c-KIT and c-KIT mutations in mastocytosis and other hematological diseases. J Leukoc Biol. 2000;67:135–148.
- Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130:804–815.
- Lasota J. Not all c-KIT mutations can be corrected by imatinib. Lab Invest. 2007;87:317.
- Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714–4716.
- Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-KIT whereas the kinase domain mutant D816V Kit is resistant. Mol Cancer Ther. 2002;1:1115–1124.
- Alvarez-Twose I, González P, Morgado JM, Jara-Acevedo M, Sánchez-Muñoz L, Matito A, et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol. 2012;30:e126–e129.